Dis Business was Quest Diagnostics’s largest segment in fiscal 2025, bringing in $10.79B of $11.04B (98%).
| Segment | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dis Business | $9.61B | $8.98B | $9.61B | $10.79B | |||||||||||||
| Clinical Laboratory Testing Business | — | — | — | — | |||||||||||||
| Ds Businesses | $274.00M | $276.00M | $258.00M | $250.00M | |||||||||||||
| All Other Operating Segments | — | — | — | — | |||||||||||||
| Total | $9.88B | $9.25B | $9.87B | $11.04B |
Quest Diagnostics brought in $11.04B from its two segments in fiscal 2025, the year ended December 31, 2025. That was up 11.8% from $9.87B in fiscal 2024. Dis Business was the largest at $10.79B (97.7%), ahead of Ds Businesses at $250.00M (2.3%).
Compared with fiscal 2024, Dis Business grew 12.2% to $10.79B, while Ds Businesses fell 3.1% to $250.00M. From fiscal 2022 to 2025, combined revenue from these segments grew from $9.88B to $11.04B, a compound annual growth rate of 3.7%. Dis Business' share of the total rose from 97.2% to 97.7%.
Subsidiary Guarantors was Quest Diagnostics’s largest revenue line in fiscal 2009, bringing in $6.14B of $7.46B (82%).
| Legal Entity | FY 2008 | FY 2009 |
|---|---|---|
| Subsidiary Guarantors | $6.00B | $6.14B |
| Parent | $829.48M | $877.94M |
| Non-Guarantor Subsidiaries | $653.18M | $767.48M |
| Eliminations | -$232.77M | -$330.52M |
| Total | $7.25B | $7.46B |
Quest Diagnostics brought in $7.46B from its four revenue lines in fiscal 2009, the year ended December 31, 2009. That was up 2.8% from $7.25B in fiscal 2008. Subsidiary Guarantors was the largest at $6.14B (82.4%), ahead of Parent at $877.94M (11.8%) and Non-Guarantor Subsidiaries at $767.48M (10.3%).
Compared with fiscal 2008, Non-Guarantor Subsidiaries grew fastest, up 17.5% to $767.48M. Every revenue line above 2% of revenue grew.
The total is net of Eliminations, which took $330.52M off revenue in fiscal 2009.
Routine Clinical Testing & Other Services was Quest Diagnostics’s largest product and service line in fiscal 2019, bringing in $4.21B of $7.73B (54%).
| Product and Service | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 |
|---|---|---|---|---|---|---|
| Routine Clinical Testing & Other Services | — | — | — | $4.21B | ||
| Routine Clinical Testing Services | $3.88B | $4.01B | $4.22B | — | ||
| Gene-Based & Esoteric (Including Advanced Diagnostics) Testing Services | $2.34B | $2.45B | $2.41B | $2.62B | ||
| Anatomic Pathology Testing Services | $624.00M | $612.00M | $578.00M | $579.00M | ||
| All Other Services | $377.00M | $335.00M | $327.00M | $321.00M | ||
| Total | $7.21B | $7.40B | $7.53B | $7.73B |
Quest Diagnostics brought in $7.73B from its four product and service lines in fiscal 2019, the year ended December 31, 2019. Quest Diagnostics regrouped these lines after fiscal 2018, so the total does not compare directly with that year's $7.53B. Routine Clinical Testing & Other Services was the largest at $4.21B (54.4%), ahead of Gene-Based & Esoteric (Including Advanced Diagnostics) Testing Services at $2.62B (33.9%) and Anatomic Pathology Testing Services at $579.00M (7.5%). The remaining line, All Other Services, brought in $321.00M.
Compared with fiscal 2018, Gene-Based & Esoteric (Including Advanced Diagnostics) Testing Services grew fastest, up 8.8% to $2.62B, while All Other Services fell the most, down 1.8% to $321.00M.
Quest Diagnostics began breaking out Routine Clinical Testing & Other Services in fiscal 2019, when it brought in $4.21B. Quest Diagnostics stopped reporting Routine Clinical Testing Services as a separate line after fiscal 2018, when it brought in $4.22B.
Quest Diagnostics (DGX) reports its revenue by segment, by legal entity and by product and service. In fiscal 2025, Dis Business was its largest segment, bringing in $10.79B (97.7% of the total), followed by Ds Businesses at $250.00M (2.3%).
Dis Business was Quest Diagnostics' largest segment in fiscal 2025, bringing in $10.79B, or 97.7% of the $11.04B total across its two segments.
Subsidiary Guarantors was Quest Diagnostics' largest revenue line in fiscal 2009, bringing in $6.14B, or 82.4% of the $7.46B total across its four revenue lines.
Routine Clinical Testing & Other Services was Quest Diagnostics' largest product and service line in fiscal 2019, bringing in $4.21B, or 54.4% of the $7.73B total across its four product and service lines.
Dis Business grew faster than Ds Businesses in fiscal 2025, up 12.2% from $9.61B to $10.79B. Ds Businesses fell 3.1% to $250.00M.
Every figure comes from Quest Diagnostics' annual financial filings, as reported. Each line keeps the name Quest Diagnostics gives it, and years follow its fiscal calendar.
Quest Diagnostics' revenue by segment goes back to fiscal 2009, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.